More recently, Professor Fu and team developed a cetuximab-based IL-10 immunocytokine (CmAb-(IL10)2) for EGFR-targeted delivery of IL-10 to tumor locations in conjunction with prolonged PKs and reduced toxicity via IL-10 regulation of IFN-γ production in DCs and enhanced CD8+ T lymphocyte-dependent antitumor responsiveness (Figure 5C). This evidence concerns the gene CD8A and neoplasm.